Optimizing Infectious Disease Denial Management with Automation

Effective infectious disease denial management is critical for ID practices managing high-cost therapies and complex patient regimens, ensuring both financial stability and uninterrupted patient care.

Infectious disease (ID) practices face unique challenges in prior authorization and subsequent denial management, particularly with high-cost antivirals, antifungals, and outpatient parenteral antibiotic therapy (OPAT). Denials for these critical treatments can disrupt patient care, strain revenue cycles, and increase administrative burden. Klivira provides an automated solution to navigate these complexities.

The Impact of Denials on Infectious Disease Practices

ID specialists frequently prescribe high-cost medications for conditions like HIV, HCV, and complex infections requiring OPAT. These therapies are often subject to stringent prior authorization requirements, leading to a higher propensity for denials based on clinical necessity or documentation gaps. Manual denial workflows can lead to timely-filing breaches and lost revenue, impacting the ability to provide essential, uninterrupted care.

Klivira's Automated Approach to Infectious Disease Denial Management

Klivira's platform integrates seamlessly into your existing EMR and revenue cycle, automating the denial management process from intake to appeal resolution. We normalize denial reasons, auto-route cases, and generate appeal packets, specifically tailoring the workflow to the unique demands of infectious disease treatments. This ensures that denials for critical antivirals, antifungals, and OPAT are addressed efficiently and accurately.

Key Automated Workflows for ID Denial Appeals

**Multi-channel Denial Ingestion:** Klivira captures denials from X12 835 (remittance advice), X12 277 (claim status), Da Vinci PAS `ClaimResponse` for PAS-conformant payers, and payer portals, providing a comprehensive view.
**Automated CARC/RARC Normalization:** Our system standardizes X12 CARC/RARC codes and payer-specific variations into a uniform denial reason taxonomy, eliminating manual parsing errors common in ID billing.
**Intelligent Appeal Routing:** Denials are automatically categorized and routed to the appropriate workflow—claim correction, appeal, or peer-to-peer—based on the normalized reason and payer policy, ensuring correct escalation for complex ID cases.
**Automated Appeal Packet Assembly:** For clinical-necessity denials related to high-cost ID drugs, Klivira pulls relevant clinical documentation from the EMR via FHIR, including updated lab results, progress notes, and prior-line therapy history, to build robust appeal packets.
**Timely-Filing Tracking & Enforcement:** Proactive deadline surfacing and automated tracking ensure that appeal windows for infectious disease treatments are never missed, a critical factor for high-cost therapies.
**Denial Pattern Detection:** Klivira surfaces recurring denial reasons by payer and ID service line, providing actionable insights to improve upstream prior authorization submissions and reduce future denials for antivirals, antifungals, and OPAT.

Addressing ID-Specific Denial Triggers

Infectious disease denials often stem from specific issues such as clinical necessity for high-cost antivirals (e.g., HCV, HIV regimens), dose justification for antifungals, or site-of-service appropriateness for OPAT. Klivira's system is designed to identify these specific triggers, enabling targeted appeal strategies that reference the necessary clinical guidelines and patient-specific documentation to support medical necessity.

Financial and Operational Impact for Infectious Disease Practices

By automating infectious disease denial management, practices can significantly reduce administrative costs and improve revenue capture. Industry benchmarks from the CAQH Index and MGMA Practice Operations and Cost Surveys highlight the substantial rework costs associated with manual denial processing. Klivira's platform helps ID practices mitigate these costs, reallocate staff time from manual tasks to patient care, and ensure consistent cash flow for specialized treatments.

Frequently asked questions

How does Klivira handle clinical necessity denials for high-cost antivirals?

Klivira automates the assembly of appeal packets by pulling comprehensive clinical documentation from your EMR via FHIR, including updated lab results, progress notes, and treatment history. This ensures that appeals for high-cost antivirals are supported by the strongest possible evidence, addressing payer requirements for medical necessity.

Can Klivira manage denials for OPAT (Outpatient Parenteral Antibiotic Therapy)?

Yes, Klivira is equipped to manage denials related to OPAT, which often involve site-of-service or duration-of-therapy challenges. Our system helps gather the necessary documentation to justify the prescribed treatment plan and setting, streamlining the appeal process for these critical therapies.

How does Klivira ensure timely filing for ID denial appeals?

Klivira's platform enforces per-payer timely-filing windows with proactive deadline surfacing. Our automated tracking system monitors appeal status and provides auto-escalations when status remains unchanged, significantly reducing the risk of missed deadlines for infectious disease claims.

What EMR integration capabilities does Klivira offer for denial management in ID?

Klivira integrates with EMRs using SMART on FHIR standards to retrieve patient data for appeal packets, including clinical notes, lab results, and medication lists. This ensures that the most current and relevant clinical information is automatically included in your infectious disease denial appeals.

Does Klivira provide insights into common denial patterns for infectious disease treatments?

Yes, Klivira's reporting and pattern detection capabilities identify recurring denial reasons by payer, service line, and provider. This feedback loop helps ID practices understand why denials occur for specific treatments like antivirals or antifungals, enabling proactive adjustments to upstream prior authorization submissions.